Oncology Archives - Insights From Our Labs to Yours

Decentralized Clinical Trials (DCT) Monthly Blog – March 2021

by Covance by Labcorpupdated on Monday, April 5, 2021Monday, March 29, 2021

Welcome to the March 2021 edition of the Covance DCT blog. This month, we want to highlight the growing connections between decentralized clinical trials (DCTs) and the critical therapeutic area of oncology.

Minimal Residual Disease by Flow Cytometry: Latest Insights on Validation

by Covance by Labcorpupdated on Monday, March 22, 2021Monday, March 22, 2021

Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome …

Innovation in Plasma Cell Enrichment for Multiple Myeloma Studies

by Covance by Labcorpupdated on Friday, January 29, 2021Monday, February 8, 2021

Syndecan-1 (SDC1), also known as CD138, is a well-known and specific plasma cell marker that is highly expressed on the surface of multiple myeloma plasma cells. As it can be a challenge detecting the small number of malignant plasma cells within the large proportion of cells obtained from a bone …

Centralized Multiple Myeloma Service Delivers on a Global Scale

by Covance by Labcorpupdated on Tuesday, January 26, 2021Monday, January 25, 2021

As the volume of multiple myeloma clinical trials continues to grow, additional tests are being validated in an effort to benefit patients who typically have a five-year survival rate. These dynamics are driving strategies to address variability in testing procedures and data analysis. We recently met with the Covance dedicated …

CRO Perspectives: Driving Innovation, Consistency and Reliability in Multiple Myeloma Clinical Trials

by Covance by Labcorpupdated on Monday, January 11, 2021Monday, January 11, 2021

Despite advances in treatment options, multiple myeloma incidence rates have increased since 1990. Drug development for this complex disease requires a unique combination of technology and expertise. In this short series of blog posts, Covance will share perspectives on multiple myeloma testing, technique and innovation that can reduce variability and …

Accelerating drug development timelines – Evolution in trial design approaches in oncology

by Covance by Labcorpupdated on Tuesday, December 22, 2020Tuesday, December 22, 2020

Three specialists – Dr. Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford; Maria Prendes, Head of Oncology at the Covance Biomarker Solution Center; and Kamal Saini, Senior Medical Director of Oncology at Covance – recently discussed this highly relevant topic in an educational webinar, which is now available …

Key Considerations for Medical Monitoring in CAR T Clinical Trials During the COVID-19 Pandemic and Beyond

by Covance by Labcorpupdated on Tuesday, November 3, 2020Tuesday, November 3, 2020

The following blog is an adaptation of a conference presentation by Covance in September 2020 that was also re-recorded and available here Background: Medical monitoring supports the correct determination of patient eligibility for CAR T-cell therapy and plays a key role in monitoring quality patient care throughout CAR T clinical …

Adapting oncology clinical research practices and therapeutic development strategies in the covid-19 era

by Covance by Labcorpupdated on Thursday, October 1, 2020Thursday, October 1, 2020

The COVID-19 outbreak that began in Wuhan, China, in December 2019 was declared a pandemic on March 11, 2020 by the World Health Organization, and has since affected almost every country around the world. Cancer patients have been significantly impacted, through both clinical practice as well as engagement and participation …

IND-Enabling programs for adoptive cell therapies

by Covance by Labcorpupdated on Wednesday, July 29, 2020Thursday, July 30, 2020

Chimeric Antigen Receptor T Cells, In Vitro and In Vivo Preclinical Models, plus regulatory and safety considerations In a recent webinar, we presented on and discussed the adoptive cell therapy preclinical program central to an IND/IMPD submission. The following is a brief summary, plus insightful Q&As from that event.

An introduction to dendritic cell biology and analysis using syngeneic immuno-oncology models

by Covance by Labcorpupdated on Tuesday, June 30, 2020Sunday, March 29, 2020

Productive immunotherapy driven anti-tumor responses rely on the activation of T cells that target tumor-associated antigens (TAA). The dendritic cell (DC) plays an essential role in the activation of T cell antigen-specific responses, which occur naturally in the context of infection. However, this same process supports tumor-immune surveillance as well …